At the 31st Annual Society for Neuro-Oncology meeting, biotech firms NeOnc, Nuvation Bio, Jazz Pharmaceuticals, and Cerenome presented new clinical data on brain cancer treatments. Highlights include NeOnc's NEO100 and NEO212 therapies advancing toward FDA discussions, Cerenome's REYOBIQ updates for leptomeningeal metastases, Nuvation's safusidenib data for IDH1-mutant gliomas, and Jazz's Phase 3 trial progress with dordaviprone. These developments could impact future treatment options and regulatory approvals for challenging brain cancers.
Nuvation Bio's stock is priced at USD 4.03 on Pluang as of Nov 14, 2026 02:12 WIB, showing a slight decline of 0.86% over one day. The company holds a market capitalization of $1.43 billion with a trading volume of 5,614,021 shares. Typical investors on Pluang hold NUVB shares for about 15 days, reflecting moderate trading activity amid the biotech developments.
